Recombinant DNA Technology Market-Trends, 2025

Recombinant DNA technology (rDNA) helps to identify the gene function and its regulation in normal and pathogenic condition. Recombinant DNA is created artificially from two or more DNA molecules, which are incorporated into a single molecule. Recombinant DNA technology examines the functioning of the living system by manipulating their genome for production of useful metabolites. Recombinant DNA technology has introduced new classes of organism namely genetically modified organism (GMO) or living modified organism (LMO).  It can develop genetically modified crops (BT cotton), cloned animals, bio pesticides, biofuel, bioremediation, and gene therapy successfully. Impact of rDNA on human and environment in the context of safety is assessed by researchers.

Advance rDNA technology have resulted in production of various therapeutic proteins, such as insulin, hormones, edible vaccines, interleukins, and monoclonal antibodies. It has enormous potential to revolutionize the medical and clinical medicines. rDNA technology has triggered the biopharmaceutical industries towards the development of various rDNA product, in turn favoring the growth of recombinant DNA technology market.

Request For Sample Copy@

Global Recombinant DNA Technology Market Taxonomy

By Types-

Expression system


Cloning vector


By Product –


Therapeutic Agent,Human Protein,Vaccines


Biotech Crops

By Application –

Health And Disease,Food And Agriculture,Environment

By End User –

Research institutes,Biotechnology companies,Pharmaceuticals

Global recombinant DNA technology market – trends and opportunity

At Jef Boeke’s lab, 2017, scientists are rewriting the yeast genome, which aims to create custom-made chunks of DNA codes, which can be inserted into the cells to alter their functions and improve drug development. Researchers intend to construct whole new organisms with functional genes, which will help to develop vaccines, proteins, drugs, and biofuels.

According to Applied Science Report, 2013, integrating biotechnology and genomics in the drug development process gives the opportunity to companies to save up to US$ 300 million per drug, which is about one-third of the cost of the drug. This prospect is bringing drug two year earlier in the market, indicating the significance of recombinant drugs and the need for manufacturing.

Increasing investments in research and development pool to favor the growth of recombinant DNA technology

Increasing government funding in the U.S. by the Department of Health And Human Services (HHS) to National Institute of Health’s research and development for various disciplinary field gene therapy applications is the major driving factor for the growth of recombinant DNA technology market. Effect of various factors, such as food, health problems, and environmental issues on growing population is another driving factor for the growth of recombinant DNA technology market. Diseases such as cancers, genetic disorder, plant and animal disorders, and development of anti-fungal or anti-viral abilities of plants have high demand in therapeutic approaches, which will favor the growth of recombinant DNA technology market.

Lack of government funding for research and development in emerging economies is the major restraint for the growth of recombinant DNA technology market.

The major key players operating the recombinant DNA technology market include Horizon Discovery Group PLC, F. Hoffmann-La Roche Ltd (Genentech, Inc), Profacgen, Cibus; Monsanto Company, Amgen Inc., New England Biolabs, Novartis AG, GenScript, GlaxoSmithKline plc, Pfizer Inc., Novo Nordisk, and Eli Lilly and Company.

Get More Details On this Report:

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Tel: +1-206-701-6702

Visit our news Website:

Designed by
Powered by
%d bloggers like this: